000 will die from the disease. It's much less common than other skin cancers and much more aggressive and likely to spread to other organs. The earliest sign is often a large misshapen or unusually colored mole that grows in size.
Median overall survival was also superior with Keytruda in patients with a PD-L1 TPS of 50% or greater (16.9 months versus 8.2 months) and a PD-L1 TPS of 1% (11.8 months versus 8.4 months), compared with docetaxel. Median progression-free survival rates were als...
“The long-term survival benefit achieved with Keytruda as a single agent in this study is a great example of the progress we have made in lung cancer to provide patients with more time without disease progression and a chance at a longer life,” Reck said...
(pembrolizumab) Demonstrated Clinical Benefit in Stage III Non-Small Cell Lung Cancer (NSCLC) and Reinforce Long-Term Survival in Metastatic NSCLC. Retrieved May 13, 2020, from https://www.mrknewsroom.com/news-release/oncology/new-combination-data-mercks-keytruda-pembrolizumab-demonstrated-clinical-be...
[1] New Combination Data for Merck’s KEYTRUDA® (pembrolizumab) Demonstrated Clinical Benefit in Stage III Non-Small Cell Lung Cancer (NSCLC) and Reinforce Long-Term Survival in Metastatic NSCLC. Retrieved May 13, 2020, from https://www.mrknewsroom.com/news-release/oncology/new-combination-da...
[1] New Combination Data for Merck’s KEYTRUDA (pembrolizumab) Demonstrated Clinical Benefit in Stage III Non-Small Cell Lung Cancer (NSCLC) and Reinforce Long-Term Survival in Metastatic NSCLC. Retrieved May 13, 2020, from https://www.mrknewsroom.com/news-release/oncology/new-combination-data-...
Finding cancer at an earlier stage may give patients a greater chance of long-term survival. Many cancers are considered most treatable and potentially curable in their earliest stage of disease. Building on the strong...
Finding cancer at an earlier stage may give patients a greater chance of long-term survival. Many cancers are considered most treatable and potentially curable in their earliest stage of disease. Building on the strong underst...
Finding cancer at an earlier stage may give patients a greater chance of long-term survival. Many cancers are considered most treatable and potentially curable in their earliest stage of disease. Building on the strong ...
KEYNOTE-689 trial shows Keytruda (pembrolizumab) produced significantly improved event-free survival and major pathological response in patients with resected, locally advanced head and neck squamous cell carcinoma, marking the first Phase III trial to show meaningful results with an anti-PD-1 therapy...